Activated Epidermal Growth Factor Receptor: Studies in head and neck tumors and tumor cell lines after exposure to ligand and receptor tirosine-kinase inhibitors
J. Baselga, M.A. Cañadas, J. Codony, J.A. Hueto, A. Arcas, A. Lladó, X. Puig, M. Guix, G. Raspall, J. Albanell.
The epidermal growth factor receptor (EGFr) is frequently overexpressed in head and neck tumors. Therapeutic strategies directed at preventing or reversing activation of the EGFr are being studied in the clinic. In this setting, assays to determinate the level of EGRr activation prior and during therapy could be instrumental to find the optimal biological dose of anti-receptor therapies. We have studied […]